Drug Week

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Bioengineering

Modigene Reports Second Quarter Financial Results

Modigene reported a net loss of $12.4 million and $12.0 million, or $0.63 and $0.46 per basic and diluted share, for the six and three months ending June 30, 2007, respectively, compared to a net loss of $0.96 million and $0.55 million, or $0.07 and $0.04 per basic and diluted share, for the six and three month periods ending June 30, 2006, respectively. The increase in net loss was primarily the result of recognition of a one-time, non-cash $11 million goodwill charge resulting from the purchase of Modigene Delaware. The goodwill was recognized...

• View Other Issues of Drug Week
  
• View Other NewsRx Publications